Once off device.
After rereading the 4c and chatting about it with a fellow investor it's actually not too bad if you dig deeper.
Last quarter they did US$135k in sales, and from this latest report are up 26% making that $170k for the quarter (if we count receivables collected in July). $170k, up from the $145k reported in December, so there's been some growth. Doing the maths, the Australian market works out to be about US$725k so that's about 24% of the market. Hoping for more, but not too bad.
The key is really getting that FDA approval and transferring successfully to the new manufacturing plant. This 4c suggested these were all on track. So certainly not a great report, but not bad. If we are able to get the same take up rate for the US market, I think we'll all be happy!
Once off device. After rereading the 4c and chatting about it...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $6.684M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 29583410 | 0.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.2¢ | 59394450 | 39 |
View Market Depth
| Last trade - 16.13pm 20/06/2025 (20 minute delay) ? |
| AXP (ASX) Chart |
Day chart unavailable